Cynosure Group LLC Acquires Shares of 2,911 Natera, Inc. (NASDAQ:NTRA)

Cynosure Group LLC bought a new position in Natera, Inc. (NASDAQ:NTRA) in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 2,911 shares of the medical research company’s stock, valued at approximately $370,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in NTRA. Itau Unibanco Holding S.A. purchased a new position in Natera in the 2nd quarter worth approximately $28,000. Quarry LP increased its holdings in shares of Natera by 148.4% in the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock worth $34,000 after purchasing an additional 190 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Natera by 50.0% in the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after purchasing an additional 108 shares during the last quarter. Covestor Ltd lifted its holdings in shares of Natera by 34.3% during the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after purchasing an additional 95 shares in the last quarter. Finally, Brooklyn Investment Group purchased a new stake in shares of Natera during the third quarter valued at $70,000. Institutional investors own 99.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on NTRA shares. The Goldman Sachs Group boosted their target price on Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. Morgan Stanley increased their price objective on shares of Natera from $132.00 to $176.00 and gave the company an “overweight” rating in a research report on Thursday, November 14th. Piper Sandler lifted their target price on shares of Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a research report on Monday, November 18th. UBS Group lowered their price target on Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a report on Friday, August 9th. Finally, JPMorgan Chase & Co. lifted their price objective on Natera from $135.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday, November 13th. One analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $140.59.

Insider Buying and Selling at Natera

In other Natera news, Director Gail Boxer Marcus sold 9,682 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $159.98, for a total value of $1,548,926.36. Following the completion of the transaction, the director now directly owns 9,704 shares in the company, valued at $1,552,445.92. This represents a 49.94 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Steven Leonard Chapman sold 5,024 shares of Natera stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $128.48, for a total transaction of $645,483.52. Following the sale, the chief executive officer now owns 195,686 shares in the company, valued at approximately $25,141,737.28. The trade was a 2.50 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 46,503 shares of company stock valued at $6,325,804 over the last ninety days. 7.60% of the stock is currently owned by company insiders.

Natera Trading Up 0.1 %

Natera stock opened at $168.45 on Friday. Natera, Inc. has a 12-month low of $53.88 and a 12-month high of $171.95. The firm has a market capitalization of $22.24 billion, a price-to-earnings ratio of -95.71 and a beta of 1.53. The firm has a 50 day moving average of $133.88 and a 200 day moving average of $119.43. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.31. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm had revenue of $439.80 million during the quarter, compared to analysts’ expectations of $361.43 million. During the same period in the prior year, the company posted ($0.95) earnings per share. The company’s revenue for the quarter was up 63.9% compared to the same quarter last year. As a group, research analysts predict that Natera, Inc. will post -1.66 earnings per share for the current year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.